IL285560B2 - Topical preparations containing a BRAF inhibitor for the treatment of dermatitis as a result of radiation - Google Patents
Topical preparations containing a BRAF inhibitor for the treatment of dermatitis as a result of radiationInfo
- Publication number
- IL285560B2 IL285560B2 IL285560A IL28556021A IL285560B2 IL 285560 B2 IL285560 B2 IL 285560B2 IL 285560 A IL285560 A IL 285560A IL 28556021 A IL28556021 A IL 28556021A IL 285560 B2 IL285560 B2 IL 285560B2
- Authority
- IL
- Israel
- Prior art keywords
- grade
- composition
- topical
- administration
- rtog
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 83
- 208000006934 radiodermatitis Diseases 0.000 title claims description 35
- 229940125431 BRAF inhibitor Drugs 0.000 title claims description 33
- 230000000699 topical effect Effects 0.000 title claims description 31
- 238000011282 treatment Methods 0.000 title claims description 24
- -1 ARQ680 Chemical compound 0.000 claims description 61
- 150000001875 compounds Chemical class 0.000 claims description 38
- 206010067484 Adverse reaction Diseases 0.000 claims description 31
- 230000006838 adverse reaction Effects 0.000 claims description 31
- 238000001959 radiotherapy Methods 0.000 claims description 31
- 230000002411 adverse Effects 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 239000003937 drug carrier Substances 0.000 claims description 16
- 102000043136 MAP kinase family Human genes 0.000 claims description 13
- 108091054455 MAP kinase family Proteins 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 13
- 238000011200 topical administration Methods 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 8
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 8
- 229960003862 vemurafenib Drugs 0.000 claims description 8
- PYEFPDQFAZNXLI-UHFFFAOYSA-N 3-(dimethylamino)-N-[3-[[(4-hydroxyphenyl)-oxomethyl]amino]-4-methylphenyl]benzamide Chemical compound CN(C)C1=CC=CC(C(=O)NC=2C=C(NC(=O)C=3C=CC(O)=CC=3)C(C)=CC=2)=C1 PYEFPDQFAZNXLI-UHFFFAOYSA-N 0.000 claims description 6
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 6
- 229960002465 dabrafenib Drugs 0.000 claims description 6
- MMNNTJYFHUDSKL-UHFFFAOYSA-N methyl n-[6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-1h-benzimidazol-2-yl]carbamate Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(C1=CC=CC=C1C1=O)(O)N1C1=CC(Cl)=CC=C1C MMNNTJYFHUDSKL-UHFFFAOYSA-N 0.000 claims description 6
- 101150009274 nhr-1 gene Proteins 0.000 claims description 6
- 229960003787 sorafenib Drugs 0.000 claims description 6
- 230000000803 paradoxical effect Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000007933 dermal patch Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 239000000017 hydrogel Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- MLSAQOINCGAULQ-QFMPWRQOSA-N (E)-SB-590885 Chemical compound C1=CC(OCCN(C)C)=CC=C1C1=NC(C=2C=CN=CC=2)=C(C=2C=C3CCC(/C3=CC=2)=N\O)N1 MLSAQOINCGAULQ-QFMPWRQOSA-N 0.000 claims description 3
- DKNUPRMJNUQNHR-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 DKNUPRMJNUQNHR-UHFFFAOYSA-N 0.000 claims description 3
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims description 3
- FIMYFEGKMOCQKT-UHFFFAOYSA-N 3,4-difluoro-2-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide Chemical compound FC=1C(F)=C(NC=2C(=CC(I)=CC=2)F)C(C(=O)NOCCO)=CC=1CN1OCCCC1=O FIMYFEGKMOCQKT-UHFFFAOYSA-N 0.000 claims description 3
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 claims description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 3
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 claims description 3
- VWMJHAFYPMOMGF-ZCFIWIBFSA-N TAK-580 Chemical compound N([C@H](C)C=1SC(=CN=1)C(=O)NC=1N=CC(Cl)=C(C=1)C(F)(F)F)C(=O)C1=NC=NC(N)=C1Cl VWMJHAFYPMOMGF-ZCFIWIBFSA-N 0.000 claims description 3
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 claims description 3
- HXINDCTZKGGRDE-JPKZNVRTSA-L disodium;[3-[5-[2-[[(3r)-1-(1-methylpyrazol-3-yl)sulfonylpiperidin-3-yl]amino]pyrimidin-4-yl]imidazo[2,1-b][1,3]oxazol-6-yl]phenoxy]methyl phosphate Chemical compound [Na+].[Na+].CN1C=CC(S(=O)(=O)N2C[C@@H](CCC2)NC=2N=C(C=CN=2)C=2N3C=COC3=NC=2C=2C=C(OCOP([O-])([O-])=O)C=CC=2)=N1 HXINDCTZKGGRDE-JPKZNVRTSA-L 0.000 claims description 3
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 229950001969 encorafenib Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 37
- 239000003112 inhibitor Substances 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 230000035755 proliferation Effects 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 239000003974 emollient agent Substances 0.000 description 10
- 230000005855 radiation Effects 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- FZPYULHBUBXPIG-UHFFFAOYSA-N C1=C(NC2=NC=CC3=C(NC4=C(C=CC=N4)C4=C5N=CNC5=NC=N4)C(C)=CC=C23)C=C(OC(F)(F)F)C=C1 Chemical compound C1=C(NC2=NC=CC3=C(NC4=C(C=CC=N4)C4=C5N=CNC5=NC=N4)C(C)=CC=C23)C=C(OC(F)(F)F)C=C1 FZPYULHBUBXPIG-UHFFFAOYSA-N 0.000 description 8
- 229940125430 LUT-014 Drugs 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 206010040844 Skin exfoliation Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000006072 paste Substances 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- 230000035618 desquamation Effects 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000003349 gelling agent Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- GNXFBMIJCZKYPN-UHFFFAOYSA-N N1=C(C=C(N1C)NC1=NC=CC2=C(NC3=C(C=CC=N3)C3=C4N=CNC4=NC=N3)C(C)=CC=C12)C(C)(C)C Chemical compound N1=C(C=C(N1C)NC1=NC=CC2=C(NC3=C(C=CC=N3)C3=C4N=CNC4=NC=N3)C(C)=CC=C12)C(C)(C)C GNXFBMIJCZKYPN-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NNPAUMAACJPWOQ-UHFFFAOYSA-N C1=C(C#C)C=C(NC2=C3C=CC(=C(NC4=C(C=CC=N4)C4=C5N=CNC5=NC=N4)C3=CC=N2)C)C=C1 Chemical compound C1=C(C#C)C=C(NC2=C3C=CC(=C(NC4=C(C=CC=N4)C4=C5N=CNC5=NC=N4)C3=CC=N2)C)C=C1 NNPAUMAACJPWOQ-UHFFFAOYSA-N 0.000 description 2
- CJQQVFISHQDCLJ-UHFFFAOYSA-N C1=CC(=C(C=C1NC1=C2C(=CC=N1)C(NC1=C(C3=C4N=CNC4=NC=N3)C=CC=N1)=C(C)C=C2)C(F)(F)F)Cl Chemical compound C1=CC(=C(C=C1NC1=C2C(=CC=N1)C(NC1=C(C3=C4N=CNC4=NC=N3)C=CC=N1)=C(C)C=C2)C(F)(F)F)Cl CJQQVFISHQDCLJ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 101710113436 GTPase KRas Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 206010063562 Radiation skin injury Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 229960001097 amifostine Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000006208 topical dosage form Substances 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 1
- KJYGRYJZFWOECQ-UHFFFAOYSA-N [2-hydroxy-3-[2-hydroxy-3-[2-hydroxy-3-(16-methylheptadecanoyloxy)propoxy]propoxy]propyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COCC(O)COC(=O)CCCCCCCCCCCCCCC(C)C KJYGRYJZFWOECQ-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940116342 acetylated sucrose distearate Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000003916 calcium stearoyl-2-lactylate Substances 0.000 description 1
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 description 1
- OEUVSBXAMBLPES-UHFFFAOYSA-L calcium stearoyl-2-lactylate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O.CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O OEUVSBXAMBLPES-UHFFFAOYSA-L 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229940023564 hydroxylated lanolin Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000009701 normal cell proliferation Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical class CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804235P | 2019-02-12 | 2019-02-12 | |
| PCT/IB2020/051073 WO2020165755A1 (en) | 2019-02-12 | 2020-02-11 | Use of topical braf inhibitor compositions for treatment of radiation dermatitis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL285560A IL285560A (en) | 2021-09-30 |
| IL285560B1 IL285560B1 (en) | 2023-12-01 |
| IL285560B2 true IL285560B2 (en) | 2024-04-01 |
Family
ID=72044789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL285560A IL285560B2 (en) | 2019-02-12 | 2020-02-11 | Topical preparations containing a BRAF inhibitor for the treatment of dermatitis as a result of radiation |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11439648B2 (https=) |
| EP (1) | EP3923911B1 (https=) |
| JP (1) | JP2022519675A (https=) |
| KR (1) | KR102534457B1 (https=) |
| CN (1) | CN113382717A (https=) |
| AU (1) | AU2020220895B9 (https=) |
| BR (1) | BR112021015137A2 (https=) |
| CA (1) | CA3127175C (https=) |
| ES (1) | ES2952251T3 (https=) |
| HR (1) | HRP20231241T1 (https=) |
| HU (1) | HUE063091T2 (https=) |
| IL (1) | IL285560B2 (https=) |
| MX (1) | MX2021009535A (https=) |
| PL (1) | PL3923911T3 (https=) |
| RS (1) | RS64618B1 (https=) |
| WO (1) | WO2020165755A1 (https=) |
| ZA (1) | ZA202106581B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116669739A (zh) * | 2020-12-24 | 2023-08-29 | 鲁特里斯制药有限公司 | 用于治疗egfr下游效应物诱导的反应的局部braf抑制剂组合物 |
| MX2024000227A (es) * | 2021-07-02 | 2024-04-16 | Lutris Pharma Ltd | Uso de isoquinolina-1,5-diaminas para la curacion de heridas. |
| WO2023051685A1 (zh) * | 2021-09-30 | 2023-04-06 | 北京大学 | 一种对红系前体细胞或成红细胞进行扩增的方法及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170100345A1 (en) * | 2014-05-06 | 2017-04-13 | The Regents Of The University Of California | Wound healing using braf inhibitors |
| US20180369247A1 (en) * | 2016-03-10 | 2018-12-27 | Lutris Pharma Ltd. | Use of braf inhibitors for treating cutaneous reactions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753612A (en) | 1992-10-27 | 1998-05-19 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| US8557830B2 (en) | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
| EP3147281A1 (en) * | 2008-03-17 | 2017-03-29 | Ambit Biosciences Corporation | Quinazoline derivatives as raf kinase modulators and methods of use thereof |
| WO2011117381A1 (en) * | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
| US20130226549A1 (en) | 2012-02-27 | 2013-08-29 | Yufeng J. Tseng | Structure-based fragment hopping for lead optimization and improvement in synthetic accessibility |
| KR20140011780A (ko) | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체 |
| JP6912667B2 (ja) * | 2017-07-29 | 2021-08-04 | ルトリス ファーマ エル ティー ディー． | 新規なｂｒａｆ阻害剤および皮膚反応を治療するためのその使用 |
| WO2019032717A1 (en) * | 2017-08-08 | 2019-02-14 | Memorial Sloan Kettering Cancer Center | USE OF BRAF INHIBITORS FOR TREATING SKIN REACTIONS CAUSED BY TREATMENT WITH MEK INHIBITOR |
-
2020
- 2020-02-11 KR KR1020217029012A patent/KR102534457B1/ko active Active
- 2020-02-11 PL PL20756229.9T patent/PL3923911T3/pl unknown
- 2020-02-11 CA CA3127175A patent/CA3127175C/en active Active
- 2020-02-11 MX MX2021009535A patent/MX2021009535A/es unknown
- 2020-02-11 IL IL285560A patent/IL285560B2/en unknown
- 2020-02-11 HU HUE20756229A patent/HUE063091T2/hu unknown
- 2020-02-11 EP EP20756229.9A patent/EP3923911B1/en active Active
- 2020-02-11 ES ES20756229T patent/ES2952251T3/es active Active
- 2020-02-11 WO PCT/IB2020/051073 patent/WO2020165755A1/en not_active Ceased
- 2020-02-11 RS RS20230855A patent/RS64618B1/sr unknown
- 2020-02-11 BR BR112021015137-0A patent/BR112021015137A2/pt unknown
- 2020-02-11 CN CN202080012207.4A patent/CN113382717A/zh active Pending
- 2020-02-11 JP JP2021545958A patent/JP2022519675A/ja active Pending
- 2020-02-11 HR HRP20231241TT patent/HRP20231241T1/hr unknown
- 2020-02-11 AU AU2020220895A patent/AU2020220895B9/en active Active
-
2021
- 2021-07-23 US US17/384,221 patent/US11439648B2/en active Active
- 2021-09-07 ZA ZA2021/06581A patent/ZA202106581B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170100345A1 (en) * | 2014-05-06 | 2017-04-13 | The Regents Of The University Of California | Wound healing using braf inhibitors |
| US20180369247A1 (en) * | 2016-03-10 | 2018-12-27 | Lutris Pharma Ltd. | Use of braf inhibitors for treating cutaneous reactions |
Non-Patent Citations (1)
| Title |
|---|
| ANKER, CHRISTOPHER J., ET AL., AVOIDING SEVERE TOXICITY FROM COMBINED BRAF INHIBITOR AND RADIATION TREATMENT: CONSENSUS GUIDELINES FROM THE EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG)., 9 November 2016 (2016-11-09) * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020165755A1 (en) | 2020-08-20 |
| PL3923911T3 (pl) | 2023-12-27 |
| ES2952251T3 (es) | 2023-10-30 |
| US20210346389A1 (en) | 2021-11-11 |
| BR112021015137A2 (pt) | 2021-09-28 |
| HRP20231241T1 (hr) | 2024-02-16 |
| EP3923911A4 (en) | 2022-11-09 |
| HUE063091T2 (hu) | 2024-01-28 |
| CN113382717A (zh) | 2021-09-10 |
| EP3923911B1 (en) | 2023-07-12 |
| JP2022519675A (ja) | 2022-03-24 |
| ZA202106581B (en) | 2022-09-28 |
| CA3127175C (en) | 2023-06-27 |
| AU2020220895A1 (en) | 2021-08-12 |
| CA3127175A1 (en) | 2020-08-20 |
| RS64618B1 (sr) | 2023-10-31 |
| AU2020220895B2 (en) | 2022-11-17 |
| AU2020220895B9 (en) | 2023-02-02 |
| IL285560A (en) | 2021-09-30 |
| IL285560B1 (en) | 2023-12-01 |
| KR20210126665A (ko) | 2021-10-20 |
| EP3923911A1 (en) | 2021-12-22 |
| KR102534457B1 (ko) | 2023-05-18 |
| MX2021009535A (es) | 2022-10-10 |
| US11439648B2 (en) | 2022-09-13 |
| EP3923911C0 (en) | 2023-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5654312A (en) | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents | |
| US11439648B2 (en) | Use of topical BRAF inhibitor compositions for treatment of radiation dermatitis | |
| CA2301009C (en) | Skin care compositions and use | |
| JP5389980B2 (ja) | 手足症候群の治療のためのアロプリノールの使用 | |
| KR20220136979A (ko) | 콜히친을 포함하는 알레르기성 피부 질환 또는 피부 소양증 치료용 조성물 | |
| JP2010184903A (ja) | 外用医薬組成物 | |
| WO2025090117A1 (en) | Compositions and methods for treatment of wounds and inflammatory skin conditions | |
| AU2014374416A1 (en) | Allantoin compositions for treating inflammatory skin conditions | |
| KR20230139402A (ko) | 염증성 피부 증후군을 치료하는 약제학적인 용도의 화장품 조성물 | |
| RU2812708C2 (ru) | Применение композиций на основе ингибитора braf для наружного применения для лечения лучевого дерматита | |
| HUT74448A (en) | Process for preparing pharmaceutical compns. contg. ibuprofen and flurbiprofen for use as anti-pruritic agents | |
| JP5033381B2 (ja) | 外用医薬組成物 | |
| KR20080011280A (ko) | 피부과학적 질병의 치료를 위한 피부과학적 조성물 및 염 | |
| JP5460766B2 (ja) | 外用医薬組成物 | |
| US20250114362A1 (en) | Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions | |
| US20060019935A1 (en) | Composition and method for treating acne including anti-inflammatory Hepes Oleate | |
| KR20250108066A (ko) | 튜불린 저해제를 포함하는 병용요법을 이용한 피부 질환 예방 또는 치료용 조성물 | |
| PL211459B1 (pl) | Zastosowanie czwartorzędowych soli pirydyniowych oraz preparat farmaceutyczny zawierający czwartorzędowe sole pirydyniowe | |
| HK40017100A (en) | Composition for preventing or treating sleep disorders | |
| CZ20002863A3 (cs) | Kosmetický způsob léčby a/nebo prevence celulitidy a průmyslový výrobek |